Andy has been with the MHRA since March 2005 as a GMP Inspector and became a Senior GMP Inspector 2009.

Claire joined the agency as a GDP Inspector in January 2013 and has a background in pharmaceutical manufacturing and auditing of 15 years. Aspects of previous roles in a large pharmaceutical company include project management, QMS implementation and Quality Assurance. She is PRINCE2 qualified and has a degree in Business.

Gaynor joined the MHRA as a GDP Inspector in May 2009 formally working in the pharmaceutical wholesale distribution industry for over 10 years as a Project Manager and Business Compliance Manager. Her roles included auditing the organisation to ensure legal compliance with regulatory bodies including compliance to GDP. Gaynor was also involved in a number of large projects including the management of a building project and the implementation of automation in a large distribution site. She has qualifications in Project Management and Health and Safety. Gaynor spent two years as the MHRA's Health and Safety Manager achieving BS18001 certification. She returned to her GDP Inspector role in July 2013 where she is a member of the implementation team for conducting inspections on API distributors and coordinator of the GDP symposium.

Peter is a pharmacist by profession and joined the MHRA in January 2013. Prior to joining the MHRA, Peter had worked in the pharmaceutical industry for over 30 years, focusing mainly on Pharmaceutical Wholesale and Retail Pharmacy.in various managerial roles including Operations Management, Regulatory Affairs, Quality Assurance and acted as Responsible Person for a number of companies in the UK. Peter has experience in the implementation of ISO 9001 and ISO 13485 Quality Systems and is an ISO Pharmaceutical Lead Auditor. He was an industry representative on the BAPW RP Committee, was instrumental in identifying some of the more recent examples of falsified medicines and is a member of the MHRA Falsified Medical Product Stakeholders Group.

Phil joined the MHRA in the Pharmacovigilance Inspectorate in July 2009. In 2010 he moved to the GDP Inspectorate, where he became a GDP Operations Manager in 2013. He is a pharmacist by profession, who initially worked in the pharmaceutical industry for over 30 years, for 4 different global pharmaceutical companies. His positions included different managerial and project leader roles at all stages of pharmaceutical development. Phil currently manages one of the GDP Inspectorates two operational teams.

Terry is an Inspector within the GDP Inspectorate at the Medicines and Healthcare products Regulatory Agency (MHRA). He joined the Agency in 2009 having previously worked over 25 years in a variety of pharmaceutical industry technical and managerial roles within R&D and QA.

A founder member of the GDP Inspectorate when it was created in 2001, he is a Senior GDP Inspector responsible for inspecting the full range of UK distribution companies. He is a member of the PIC/S GDP working group, working on the training and aligning of GDP standards for PIC/S member countries. He was part of the EMA GDP drafting group preparing the GDP Guidelines and updates to the compilation of community procedures and involved in training the GMDP inspectors on the new guidelines. He was also a member of the team who reviewed the UK supply chain and looked at ways to improve the standard of the Wholesale Dealer 'Responsible Person'. He is currently a member of the implementation team for the Falsified Medicines Directive and working on developing the new Risk Based Inspection IT system for the MHRA. Tony has been with the MHRA for 24 years, working initially with the MHRA Enforcement Group where he was a Senior Investigation Officer. As such he was responsible for investigating counterfeit medicines, internet sales and other illegal activity with pharmaceuticals.

Madeleine is a senior GDP inspector and joined the MHRA in August 2009. Her previous experience includes NHS pharmacy manufacturing, project management in NHS Blood and Transplant and some teaching within the NHS. Recent projects include working with Cogent to develop the RP Gold Standard and working with the Maritime and Coastguard Agency to improve compliance within the marine sector. Madeleine enjoys contributing to inspector development and inspection consistency. Madeleine is registered with the General Pharmaceutical Council.

Vivian joined the MHRA as a GMP Inspector in 2009. She inspects both sterile and non-sterile manufacturing operations. Her other inspection areas include Good Distribution Practice and importation activities, IMP and QC contract laboratories. She is also a member of the Blood Inspection Team. Prior to joining the MHRA, Vivian had worked in the pharmaceutical industry for over 15 years in variety of roles including Quality Control, Manufacturing Operations, Quality Assurance and Supplier Management.

Andrew joined the MHRA in January 2003 as a GLP inspector. In 2004 Andrew was appointed Operations Manager for the Good Laboratory Practise and Good Distribution Practise Groups, taking responsibility for the management of a team of ten inspectors. In May 2006 Andrew took on the role of Heads of the United Kingdom Good Laboratory Monitoring Authority. In this capacity he holds the chair of the OECD GLP Working Group and is a member of the EC GLP Working Group. Andrew has contributed to a number of national and international guidance documents including the first comprehensive European guidance for laboratories that perform the analysis of samples collected as part of clinical trials. In 2014 Andrew was appointed to the role of Unit Manager Inspectorate Operations with responsibility for the GLP, GCP and GDP inspection teams. Prior to joining the MHRA, Andrew worked in academia for a number of years performing research on the underlying causes of cardiovascular disease before moving into the pharmaceutical sector where he was involved in pre-clinical drug development.

Jacqueline joined GDP in 2011, having previously worked as a Scientific Assessor in the MHRA Licensing Division. Jacqueline have a degree in Pharmacology and previously worked at the Toxicology Unit at Imperial College, London.

Peter joined the MHRA in 1993, having spent the previous three years with the Department of Health and NHS Management Executive in Leeds. Peter initially worked in the Enforcement Group and was responsible for conducting a two-year project into the use of Traditional Chinese Medicines in the UK before managing the unit's criminal prosecution team. Peter joined the GDP Inspectorate in June 2002 and became an Operations Manager in November 2011. Peter currently manages one of the GDP Inspectorates two operational teams.

Cheryl joined the MHRA as a GDP inspector in 2005. Cheryl is a Chartered Chemist and spent many years working within industry as a research chemist during which time she filed a number of patents both European and Worldwide. She has extensive experience working within Project and Programme Management roles with responsibility for a wide range of projects spanning various scientific and engineering disciplines. As well a performing a full range of GDP inspections nationwide, Cheryl was the MHRA representative on the GDP drafting Group at the EMA. Since the current guidance has been implemented, Cheryl has been leading the project to raise awareness within the medicines supply chain that companies and sites not previously regulated are impacted by the change in legislation.

Richard joined the MHRA as a GMP Inspector in 2001 and is currently a Unit Manager with responsibility for the GMP and GPvP Inspection teams. Prior to joining the MHRA Richard worked in the pharmaceutical industry for over 17 years focusing mainly on the manufacture of bulk active pharmaceutical ingredients. He has experience of process development and technical support and has held managerial positions in both QA and production. Whilst at the MHRA, in addition to the inspection of a wide range of pharmaceutical manufacturers, Richard has been an Operations Manager with responsibility for teams of both GMP and GDP Inspectors and has most recently been part of the Agency team responsible for implementing the changes arising from the Falsified Medicines Directive.

Mark joined the MHRA in 2002 and is currently the Group Manager for the Inspectorate which comprises of over 80 Inspectors. Mark is a chemistry graduate with an MSc in pharmaceutical sciences. He previously worked in the pharmaceutical industry for over 10 years in a variety of roles including process technology, new product introduction and quality assurance and he is eligible to be named as a Qualified Person under Directive 2001/83/EC.

David has been a GMP inspector with the UK Medicines and Healthcare Products Regulatory Agency since 2004. In his current role, David is the MHRA's representative at the EMA Inspectors Working Group and leads the agency team responsible for delivering data integrity inspection strategy and training. He is co-chair of the PIC/S data integrity working group. From 2012 to the end of 2015, David led the GMP Inspectorate's compliance management activity, including membership of the MHRA's Inspection Action Group. Prior to joining the MHRA, he was a Principal Pharmacist and production manager in the UK's National Health Service, responsible for the manufacture of aseptically prepared radioactive diagnostic agents, chemotherapy and parenteral nutrition products.

Ewan joined the MHRA as a GMP inspector in January 2013. Prior to joining the Agency he worked in the Pharmaceutical industry for approximately 19 years in positions which included R&D, Scale-up, Process Validation, Outsourcing, Regulatory Affairs and Quality Assurance.

Bio Available Soon

Bio Available Soon

Bio Available Soon

Bernadette is a GDP Inspector and joined the MHRA in March 2005. Her previous experience includes local government enforcement duties within a Trading Standards environment. Bernadette spent 10 years working as an Investigator within the MHRA Enforcement and Intelligence division dealing with criminal investigations. She has played an important role in the year on year success of the MHRA's Operation Pangea which focuses on the illegal internet trade of medicines and medical devices globally. In 2015, �15.8 million worth of fake medicines and devices were seized during UK operations. Bernadette is an accredited Counter Fraud Specialist.

Bio Available Soon

Bio Available Soon

Bio Available Soon